The use of cross-linked hemoglobin in treating subarachnoid...

Details The use of cross-linked hemoglobin in treating subarachnoid... The use of cross-linked hemoglobin in treating subarachnoid...

A - Human Necessities

61

K

A61K 38/42 (2006.01)

Patent

CA 2191952

Cross-linked hemoglobin infusion following subarachnoid hemorrhage dramatically reduces the tissue area of hypoperfusion and reduces the extent of neuronal damage in the area of hypoperfusion. A therapeutically effective dose ranges from about 1000-5500 mg of body weight and may be administered up to 72 hours after the onset of hemorrhage.

La perfusion d'hémoglobine réticulée après une hémorragie sous-arachnoïdienne réduit de façon spectaculaire la surface de tissu en hypoperfusion, et réduit l'étendue des dommages neuronaux dans la zone d'hypoperfusion. La dose thérapeutiquement efficace est de l'ordre d'environ 1000 à 5500 mg par kg du poids du corps. Ce traitement peut être administré jusqu'à 72 h après la survenue de l'hémorragie.

Affiliated with

Also associated with

Rating

The use of cross-linked hemoglobin in treating subarachnoid... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with The use of cross-linked hemoglobin in treating subarachnoid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and The use of cross-linked hemoglobin in treating subarachnoid... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1603484